Who receives lipid-lowering drugs: The effects of comorbidities and patient characteristics on treatment initiation

British Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2003, Pages 288-298

  Yang, Chen Chang ^a,b,c,d   Jick, Susan S ^d   Testa, Marcia A ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidity; General Practice Research Database; Hydroxymethylglutaryl CoA reductase inhibitors; Hyperlipidaemia; Lipid lowering drugs

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; NITRATE; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMORBIDITY; CONGESTIVE HEART FAILURE; DATA BASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG INDICATION; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

ADULT; AGED; ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 0037350797     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01724.x     Document Type: Article

References (39)

1. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary heart disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
2. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
3. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245.
4. Dorr AE, Gundersen K, Schneider JC, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolaemic patients - effect on serum cholesterol and mortality. J Chronic Dis 1978; 31: 5-14.
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
6. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. Br Med J 1998; 317: 1134-1135.
7. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Hlth Med 2000; 22: 275-279.
8. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
9. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-3216.
10. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-2188.
11. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
12. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002; 53: 101-105.
13. Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Aging comorbidity, and reduced rates of drug treatment for diabetes mellitus. J Clin Epidemiol 1999; 52: 781-790.
14. Lanes SF, Garcia Rodriguez LA, Hwang E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen, and indomethacin. Pharmacoepidemiol Drug Safety 2000; 9: 113-117.
15. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001; 12: 682-689.
16. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
17. Safeer RS, Lacivita CL. Choosing drug therapy for patients with hyperlipidemia. Am Fam Physician 2000; 61: 3371-3382.
18. Oster G, Borok GM, Menzin J, et al. Cholesterol-Reduction Intervention Study (CRIS). Arch Intern Med 1996; 156: 731-739.
19. Beggs PW, Clark WJ, Williams SM, Coulter DM. A comparison of the use, effectiveness, and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Program (IMMP). Br J Clin Pharmacol 1999; 47: 99-104.
20. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-1131.
21. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross national study. JAMA 1998; 279: 1458-1462.
22. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid- lowering drugs. Med J Aust 1996; 164: 208-211.
23. Jick J, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
24. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-349.
25. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chromic Dis 1987; 40: 373-383.
26. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-1079.
27. Yang CC. Predictors of Drug Utilization and Certain Pharmacological Effects of Lipid-Lowering Drugs in the United Kingdom. Doctoral Thesis. Harvard: Harvard University, Archives, Department of Epidemiology, 2002.
28. Packham C, Pearson J, Robinson J, Gray D. Use of statins in general practice. 1996-1998 cross sectional study. Br Med J 2000; 320: 1583-1584.
29. Jackevicius CA, Anderson G, Leiter L, Tu J. Use of statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001; 161: 183-188.
30. Larsen J, Andersen M, Kragstrup J. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol 2001; 57: 343-348.
31. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711-717.
32. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia. Guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-369.
33. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
34. NHS Executive. Standing Medical Advisory Committee on Use of Statins. London: Department of Health, 1997.
35. Wood D, Durrington P, McInnes G, Poulter N, Rees A, Wray R, for the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80: S1-S29.
36. Oki JC. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Pharmacotherapy 1995; 15: 317-337.
37. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
38. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
39. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.